AtlasDigestiveDigestive diseases

Gallbladder and biliary diseases

2Disease-modifyingAI-generated
Burden-over-time charts — how many people this disease affects and whether that number is rising or falling — are coming to this page. The treatability read, milestones, and live trial pipeline below are current.

Milestones

dot size = significance
199020002010202020252009 — Tocofersolan approved (FDA)2016 — Obeticholic acid approved (FDA)2018 — Fish oil triglycerides approved (FDA)2021 — Maralixibat approved (FDA)2021 — Odevixibat approved (FDA)2024 — Seladelpar approved (FDA)2024 — Elafibranor approved (FDA)
2009: Drug approval — Tocofersolan approved (FDA). 2016: Drug approval — Obeticholic acid approved (FDA). 2018: Drug approval — Fish oil triglycerides approved (FDA). 2021: Drug approval — Maralixibat approved (FDA). 2021: Drug approval — Odevixibat approved (FDA). 2024: Drug approval — Seladelpar approved (FDA). 2024: Drug approval — Elafibranor approved (FDA)

What's being tested now

2004: 1 trials started2006: 1 trials started2010: 2 trials started2011: 1 trials started2013: 3 trials started2014: 2 trials started2015: 3 trials started2016: 7 trials started2017: 10 trials started2018: 6 trials started2019: 12 trials started2020: 18 trials started2021: 25 trials started2022: 30 trials started2023: 52 trials started2024: 93 trials started2025: 123 trials started2026: 119 trials started201020202026123

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

See all 483 active Acute Cholecystitis trials on Clin2 →

Related

Burden estimates: IHME Global Burden of Disease Study. Drug indications: ChEMBL (CC BY-SA). Trial data: ClinicalTrials.gov via Clin2. Velocity, acceleration, and turning points are computed by Clin2 — how this page is made. Treatability describes what medicine can do, not what is available everywhere. This page describes populations, not people, and is not medical advice.